Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma

Journal of the American Academy of Dermatology

Volumn 50, Issue 5, 2004, Pages 783-785

  Treudler, Regina ^a,b   Georgieva, Juliana ^a,b   Geilen, Christoph C ^a,b   Orfanos, Constantin E ^a,b  

^a Campus Benjamin Franklin ^*

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DERMATITIS; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MELANOMA; PATCH TEST; PHOTOTOXICITY; PRIORITY JOURNAL; RADIOSENSITIVITY; ULTRAVIOLET A RADIATION;

EID: 2342595867     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.12.016     Document Type: Article

References (12)

1. Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, et al. Dacarbazine and interferon alfa with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001;84:1036-42.
2. Ippen H. [Light-caused skin reaction in dacarbazine therapy.] Dtsch Med Wochenschr 1980;105:531. German.
3. Bourry C, Naveau C, Lazrak K, Celerier P, Pasquiou C. First case of urticaria due to dacarbazine. Therapie 1995;50:588-589.
4. Giguere JK, Douglas DM, Lupton GP, Baker JR, Weiss RB. Procarbazine hypersensitivity manifested as a fixed drug eruption. Med Pediatr Oncol 1988;16:378-80.
5. Kennedy RD, McAleer JJ. Radiation recall dermatitis in a patient treated with dacarbazine. Clin Oncol 2001;13:470-2.
6. Kim H, Likhari P, Parker ÅD, Statkevich P, Marco A, Lin CD, et al. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 2001;24:461-468.
7. Aatmani ME, Poujol S, Astre C, Malosse F, Pinguet F. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. Am J Health Syst Pharm 2002;59:1351-1356.
8. Asahi M, Matsushita R, Kawahara M, Ishida T, Emoto C, Suzuki N, et al. Causative agent of vascular pain among photodegradation products of dacarbazine. J Pharm Pharmacol 2002;54:1117-1122.
9. Frick S, Lischner S, Rosien F, Haacke TC, Schafer F, Christophers E, et al. Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis. Hautarzt 2002;53:659-665.
10. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003;21:2551-7.
11. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-52.
12. Tsang LL, Quarterman CP, Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991;27:342-6.